2020 FULL YEAR RESULTS & OUTLOOK 2021

Halle (Saale)/Munich, April 30, 2021

IMPORTANT NOTICE AND DISCLAIMER

This Presentation has been prepared and issued by Vivoryon Therapeutics (the "Company") and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts and nothing in this Presentation is or should be relied on as a promise or representation as to the future.

All statements other than statements of historical fact included in this Presentation are or may be deemed to be forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Company, estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This Presentation does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published financial statements of the Company.

This Presentation, including any forward-looking statements, speaks only as of the date of this Presentation. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness, and any reliance a recipient places on them will be at the recipient's sole risk. No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its respective directors, officers, employees, affiliates, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any of them for any such information or opinions. The information set out herein may be subject without notice to updating, revision, verification and amendment which may materially change such information.

This Presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

WELCOME TO VIVORYON THERAPEUTICS

- on the call today -

Dr. Ulrich Dauer
Chief Executive Officer

Florian Schmid
Chief Financial Officer

Dr. Michael Schaeffer
Chief Business Officer

AGENDA

01 HIGHLIGHTS IN 2020

02 R&D UPDATE AND OUTLOOK

03 CORPORATE UPDATE AND OUTLOOK

04 FINANCIALS 2020

05 CLOSING REMARKS

06 Q&A



01 HIGHLIGHTS IN 2020

HIGHLIGHTS 2020

Highlights

- Start of development program for meprin protease inhibitors with intended therapeutic use in fibrosis and cancer
- Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease Study with Varoglutamstat
- Receive of FDA's IND approval for varoglutamstat's Phase 2 Study in Alzheimer's Disease
- Designed US VIVIA-MIND Phase 2a study with NIH funding and a seamless stage gate to Phase 2b
- Successfully completed conversion of Vivoryon Therapeutics AG int Vivoryon Therapeutics N.V. under Dutch law

Post-Period

- Appointed Florian Schmid as Chief Financial Officer



02 R&D UPDATE AND OUTLOOK

SUBSTANTIAL PIPELINE PROGRESS

VAROGLUTAMSTAT (PQ912) IN CLINICAL PHASE 2

A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of Varoglutamstat (PQ912) in Subjects with Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease.

recruiting

A Phase 2a Randomized Double-Blind Placebo-controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimer's Disease with a Stage Gate to Phase 2B (VIVA-MIND)

set for recruiting from summer 2021

Both Phase 2 trials are complementing each other:

Primary cognition read-outs: EU/NTB, US/CDR-SB
Aligned analytics: Elecsys, EEG, biomarker
In total: 664 patients

Targeting N3pG:

Novel MoA validated by Saphir phase 2a trial and Lilly's Phase 2 Donanemab data


RESEARCH Open Access

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial

QPCTL INHIBITORS IN ONCOLOGY: DUAL MoA

- Targeting the CD47-SIRPa innate immune system checkpoint. First-in-class small molecule approach, to boost anti tumor antibody therapies
- First-in-class approach to destabilize and deactivate the tumorigenic and pro-inflammatory chemokine CCL2.

- Extended patent portfolio including both composition of matter and indication coverage with expirations beyond 2034

MEPRIN: A NOVEL FIBROSIS TARGET

- Protease critical for collagen re-modelling and for the activation of inflammatory cytokines (IL-1, IL6…)
- Target indications: AKI, CKD, Fibrosis and Cancer
- Animal proof-of-concept in AKI model
- Portfolio of nanomolar inhibitors selective for Meprin a and b or both.
- PCTs 2017, 2018, & later
- Unique recognition site allows for design of selective and specific inhibitors
- Potential of early phase co-development deal





03 CORPORATE UPDATE AND OUTLOOK

CONVERSION OF VIVORYON INTO AN N.V. SUCCESSFULLY COMPLETED

Rationale for the conversion of Vivoryon's legal form:

AG → N.V.

- Increasing competitiveness in
  - Fulfillment of capital market requirements
  - Expansion of strategic options
  - Exploitation of favorable market conditions
  - Attraction of international investors
- Straightening out ambiguities resulting from two different jurisdictions

Decision backed by strong shareholder support with 97.6% of shareholder votes present at the AGM 2020

SHAREHOLDERS AND STOCK

Shareholder structure[1]



Stock

ISIN:	NL00150002Q7
WKN:	A2QJV6
Ticker symbol:	VVY
Types of shares:	Bearer shares
Number of shares	19,975,482
Stock exchange:	Euronext Amsterdam XETRA, Frankfurt
Liquidity provider:	Kempen & Co.
Listing agent:	Kempen & Co.
First trading day:	27 October 2014
52 week high/low	€ 9.50 / € 3.62

Share Price



1: as of January 18, 2021 and Management assumption

04 FINANCIALS 2020

KEY FINANCIAL HIGHLIGHTS (P&L): ACCORDING TO IFRS

IN €k	2020	2019	%
Research and development expenses	(13,210)	(4,789)	175.8
General and administrative expenses	(2,807)	(3,062)	(8.3)
Other operating income	6	59	(89,8)
Operating loss	(16,510)	(7,823)	105.5
Finance income	105	0	
Finance expenses	(604)	(31)	1,848.4
Net loss for period	(16,510)	(7,823)	111.0

OPERATING LOSS (€k)



NET LOSS (€k)



KEY FINANCIAL FIGURES (ACCORDING TO IFRS)

In €k	Dec 31, 2020	Dec 31, 2019
Earnings, Financial and Net Assets Position		
Operating loss	(16,011)	(7,792)
Finance result	(499)	(31)
Net loss for the period	(16,510)	(7,823)
Total equity	26,221	42,665
Equity ratio (end of the year) (in %)	88.1%	93.0 %
Balance sheet total (end of the year)	29,751	45,861
Cash flows used in operating activities (year)	(14,012)	(11,607)
Cash flows used in operating activities (monthly average)	(1,168)	(967)
Cash flows used in investing activities (year)	(640)	(47)
Cash flows provided by financing activities (net)	(90)	49,354
Cash and cash equivalents at the end of period	26,306	41,524
Vivoryon Therapeutics-Share	19,975,482	19,975,482
Loss per share (basic and diluted) (in EUR)	(0.83)	(0.62)



05 CLOSING REMARKS

FINANCIAL CALENDAR 2021



June 01, 2021	Interim Management Statement Q1 2021
June 28, 2021	Annual General Meeting 2021
September 21, 2021	Interim Report, Half Year Results 2021
November 23, 2021	Interim Management Statement Q3 2021



06 Q&A



vivoryon
therapeutics

www.vivoryon.com

Halle (Saale)
Weinbergweg 22
06120 Halle (Saale)
Germany

Munich
Franz-Josef-Delonge-Str. 5
81249 München
Germany

info@vivoryon.com
+49 (0)345 555 99 00



APPENDIX